SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fourth quarter and fiscal year ended July 31, 2011 (“fiscal 2011”).
Revenue for fiscal 2011 was $464,000, compared with revenue of $1,436,000 for the year ended July 31, 2010 (“fiscal 2010”). The net loss for fiscal 2011 was $8,349,000, or $0.22 per share, compared with a net loss of $6,760,000, or $0.20 per share, in fiscal 2010.
